UK markets closed
  • NIKKEI 225

    26,431.55
    -722.28 (-2.66%)
     
  • HANG SENG

    17,855.14
    -78.13 (-0.44%)
     
  • CRUDE OIL

    76.34
    -2.40 (-3.05%)
     
  • GOLD FUTURES

    1,629.30
    -26.30 (-1.59%)
     
  • DOW

    29,260.81
    -329.60 (-1.11%)
     
  • BTC-GBP

    17,887.14
    +135.30 (+0.76%)
     
  • CMC Crypto 200

    438.96
    +5.86 (+1.35%)
     
  • ^IXIC

    10,802.92
    -65.00 (-0.60%)
     
  • ^FTAS

    3,841.45
    -7.23 (-0.19%)
     

Quantum Genomics (ALQGC): Initiation — A fresh take on cardiovascular medicine

·3-min read

Edison Investment Research Limited
Quantum Genomics (ALQGC): Initiation — A fresh take on cardiovascular medicine
31-Aug-2022 / 08:55 GMT/BST

 

London, UK, 31 August 2022

 

Quantum Genomics (ALQGC): Initiation — A fresh take on cardiovascular medicine

Quantum Genomics is focused on the development of new classes of cardiovascular medicines. Firibastat, the company’s lead clinical asset, is in development for the management of treatment-resistant hypertension (TRH) and post-myocardial infarction heart failure (post-MI HF). We value Quantum Genomics at €701.3m or €20.3 per share, with 92% of this attributable to firibastat in TRH. In the near term, readouts from two Phase III trials in TRH are the main catalyst for the company. In our view, firibastat’s unique mechanism of action offers the potential for significant differentiation in the sizeable cardiovascular drug market. If results from Phase III are positive, the company could file an NDA with the FDA by end-2023. With a handful of licensing deals already in place, we see the timely signing of licensing deals in the United States and EU5 as essential to maximising the commercial success of firibastat. We estimate that, post the capital raise, end-April net cash was c €20.5m, providing a runway into Q223.

 

We value Quantum Genomics at €701.3m or €20.3 per share, based on a risk-adjusted NPV for firibastat in TRH and post-MI HF, including an estimated net cash position of €20.5m at end-April 2022. We apply a discount rate of 12.5% and assume a licensing deal for the United States and EU5 will be found pre-commercialisation of firibastat in TRH (estimated launch in 2024), in line with the company’s strategy.


Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Soo Romanoff +44 (0)20 3077 5700 healthcare@edisongroup.com

Dr Harry Shrives +44 (0)20 3077 5700 healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        www.linkedin.com/company/edison-group-/

Twitter           www.twitter.com/Edison_Inv_Res

YouTube       www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

show this
show this